FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007486550> ?p ?o ?g. }

• W2007486550 endingPage "1281" @default.
• W2007486550 startingPage "1273" @default.
• W2007486550 abstract "Objective. To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors of discontinuation in patients with rheumatoid arthritis (RA). Methods. This retrospective analysis used data from RADIUS 1, a 5-year observational registry of patients with RA, to determine time to first- and second-course discontinuation of etanercept, infliximab, and adalimumab. First-course therapy was defined as first exposure to anti-TNF therapy, and second-course therapy was defined as exposure to anti-TNF therapy after the first discontinuation. Kaplan-Meier survival analysis was used to assess persistence, log-rank tests were used to compare therapies, and Cox proportional hazards models were used to assess potential predictors of treatment discontinuation. Results. This analysis included 2418 patients. Mean persistence rates were similar among treatments [first-course: etanercept, 51%; infliximab, 48%; adalimumab, 48% (followup was 54 weeks for etanercept and infliximab and 42 weeks for adalimumab); second-course: 56%, 50%, 46%, respectively (followup was 36 weeks for etanercept and infliximab and 30 weeks for adalimumab)]. Discontinuations of first-course therapy due to ineffectiveness were similar among treatments (etanercept, 19%; infliximab, 19%; adalimumab, 20%) and discontinuations due to adverse events were significantly (p = 0.0006) lower for etanercept than for infliximab (etanercept, 14%; infliximab, 22%; adalimumab, 17%). Predictors from univariable analysis of first- or second-course therapy discontinuation included increased comorbidities (etanercept), female sex (infliximab), Clinical Disease Activity Index > 22 (infliximab), and a Stanford Health Assessment Questionnaire score > 0.5 (adalimumab). Conclusion. In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to adverse events was lower with etanercept compared with infliximab." @default.
• W2007486550 created "2016-06-24" @default.
• W2007486550 creator A5021255737 @default.
• W2007486550 creator A5032801878 @default.
• W2007486550 creator A5047233668 @default.
• W2007486550 creator A5059093901 @default.
• W2007486550 creator A5070559051 @default.
• W2007486550 creator A5080646462 @default.
• W2007486550 creator A5081762839 @default.
• W2007486550 date "2011-05-15" @default.
• W2007486550 modified "2023-10-12" @default.
• W2007486550 title "Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry" @default.
• W2007486550 cites W1966439074 @default.
• W2007486550 cites W1979364075 @default.
• W2007486550 cites W1985763670 @default.
• W2007486550 cites W1995228104 @default.
• W2007486550 cites W1996472975 @default.
• W2007486550 cites W1996597661 @default.
• W2007486550 cites W1999777294 @default.
• W2007486550 cites W2000119601 @default.
• W2007486550 cites W2006566716 @default.
• W2007486550 cites W2010363255 @default.
• W2007486550 cites W2015993259 @default.
• W2007486550 cites W2046628605 @default.
• W2007486550 cites W2098767548 @default.
• W2007486550 cites W2099199787 @default.
• W2007486550 cites W2101760942 @default.
• W2007486550 cites W2108650270 @default.
• W2007486550 cites W2116843833 @default.
• W2007486550 cites W2120069724 @default.
• W2007486550 cites W2129400639 @default.
• W2007486550 cites W2133541603 @default.
• W2007486550 cites W2149553288 @default.
• W2007486550 cites W2152348310 @default.
• W2007486550 cites W2158058290 @default.
• W2007486550 cites W2163817180 @default.
• W2007486550 cites W2314052274 @default.
• W2007486550 cites W2319957449 @default.
• W2007486550 cites W2340084730 @default.
• W2007486550 doi "https://doi.org/10.3899/jrheum.101142" @default.
• W2007486550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21572150" @default.
• W2007486550 hasPublicationYear "2011" @default.
• W2007486550 type Work @default.
• W2007486550 sameAs 2007486550 @default.
• W2007486550 citedByCount "79" @default.
• W2007486550 countsByYear W20074865502012 @default.
• W2007486550 countsByYear W20074865502013 @default.
• W2007486550 countsByYear W20074865502014 @default.
• W2007486550 countsByYear W20074865502015 @default.
• W2007486550 countsByYear W20074865502016 @default.
• W2007486550 countsByYear W20074865502017 @default.
• W2007486550 countsByYear W20074865502018 @default.
• W2007486550 countsByYear W20074865502019 @default.
• W2007486550 countsByYear W20074865502020 @default.
• W2007486550 countsByYear W20074865502021 @default.
• W2007486550 countsByYear W20074865502022 @default.
• W2007486550 countsByYear W20074865502023 @default.
• W2007486550 crossrefType "journal-article" @default.
• W2007486550 hasAuthorship W2007486550A5021255737 @default.
• W2007486550 hasAuthorship W2007486550A5032801878 @default.
• W2007486550 hasAuthorship W2007486550A5047233668 @default.
• W2007486550 hasAuthorship W2007486550A5059093901 @default.
• W2007486550 hasAuthorship W2007486550A5070559051 @default.
• W2007486550 hasAuthorship W2007486550A5080646462 @default.
• W2007486550 hasAuthorship W2007486550A5081762839 @default.
• W2007486550 hasBestOaLocation W20074865501 @default.
• W2007486550 hasConcept C126322002 @default.
• W2007486550 hasConcept C141071460 @default.
• W2007486550 hasConcept C17991360 @default.
• W2007486550 hasConcept C197934379 @default.
• W2007486550 hasConcept C2777138892 @default.
• W2007486550 hasConcept C2777226972 @default.
• W2007486550 hasConcept C2777575956 @default.
• W2007486550 hasConcept C2778715236 @default.
• W2007486550 hasConcept C2780132546 @default.
• W2007486550 hasConcept C2908647359 @default.
• W2007486550 hasConcept C71924100 @default.
• W2007486550 hasConcept C99454951 @default.
• W2007486550 hasConceptScore W2007486550C126322002 @default.
• W2007486550 hasConceptScore W2007486550C141071460 @default.
• W2007486550 hasConceptScore W2007486550C17991360 @default.
• W2007486550 hasConceptScore W2007486550C197934379 @default.
• W2007486550 hasConceptScore W2007486550C2777138892 @default.
• W2007486550 hasConceptScore W2007486550C2777226972 @default.
• W2007486550 hasConceptScore W2007486550C2777575956 @default.
• W2007486550 hasConceptScore W2007486550C2778715236 @default.
• W2007486550 hasConceptScore W2007486550C2780132546 @default.
• W2007486550 hasConceptScore W2007486550C2908647359 @default.
• W2007486550 hasConceptScore W2007486550C71924100 @default.
• W2007486550 hasConceptScore W2007486550C99454951 @default.
• W2007486550 hasIssue "7" @default.
• W2007486550 hasLocation W20074865501 @default.
• W2007486550 hasLocation W20074865502 @default.
• W2007486550 hasOpenAccess W2007486550 @default.
• W2007486550 hasPrimaryLocation W20074865501 @default.
• W2007486550 hasRelatedWork W1555548379 @default.
• W2007486550 hasRelatedWork W1973470095 @default.
• W2007486550 hasRelatedWork W1976481621 @default.

• next